




RealRate

PHARMACEUTICAL 2017

BIOXYTRAN INC

Rank 299 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

BIOXYTRAN INC Rank 299 of 313

The relative strengths and weaknesses of BIOXYTRAN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIOXYTRAN INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 659% points. The greatest weakness of BIOXYTRAN INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 1,199% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,598%, being 1,182% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	27
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	342
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	96
Other Liabilities	0
Other Net Income	-25
Property and Equipment	25
Research and Development	0
Revenues	246
Selling, General and Administrative Expense	821

Output Variable	Value in 1000 USD
Assets	52
Liabilities	342
Expenses	918
Stockholders Equity	-291
Net Income	-697
Comprehensive Net Income	-697
Economic Capital Ratio	-1,598%

